All Blogs
Jan 22, 2026
Sonomotion Secures FDA Clearance for Break Wave™ Lithotripsy System; Aidoc Earns FDA Clearance for Comprehensive AI Foundation Model in Healthcare; BD and Ypsomed Deepen Partnership to Serve Expanding Biologics Market; Omnia Medical Launches FDA-Approved PsiF DNA™ System to Market; Kardium Publishes PULSAR Pivotal Trial Findings in JACC; NEURO PMR Data Validates Hyperfine’s Diagnostic Precision and Patient-Centered Care
Sonomotion Announced FDA Clearance for its Break Wave™ Lithotripsy Device for Treatment of Kidney Stones On January 21, 2026, SonoMotion, a venture-backed medical device company focused on developing non-invasive solutions for kidney stone treatment, announced that it had received U.S. Food and Drug Admini...
Read More...
Jan 21, 2026
The Evolution of Vascular Access Devices in Modern Medicine
In the intricate world of modern clinical practice, the ability to safely and reliably access a patient's circulatory system is perhaps the most fundamental requirement of acute and chronic care. Vascular Access Devices (VADs), ranging from simple peripheral catheters to complex implanted ports, serve as the "highw...
Read More...
Jan 20, 2026
Nxera Pharma Confirms Positive Phase 3 Findings for Daridorexant in South Korea; AstraZeneca Strengthens Oncology Pipeline in China With GPC3 Armored CAR-T Rights From AbelZeta; AbbVie Shares Topline Findings from Phase 3 EPCORE DLBCL-1 Study of Epcoritamab; ImmunityBio Achieves Prolonged Complete Response Using Chemotherapy-Free CD19 CAR-NK Platform; Sobi Wins EU Approval for ASPAVELI to Treat C3G and Primary IC-MPGN
Nxera Pharma Reports Positive Phase 3 Trial Results for Daridorexant in South Korea Nxera Pharma announced top-line results from its pivotal Phase 3 clinical trial of daridorexant in South Korea, showing that the study successfully met both primary and secondary endpoints in adult and elderly patients with insom...
Read More...
Jan 19, 2026
Chronic Venous Insufficiency Treatment: Bridging Unmet Needs with Minimally Invasive and Regenerative Solutions
Summary In the seven major markets (7MM: US, EU4, UK, Japan), diagnosed cases of CVI reached ~17 million in 2024. Prevalence is projected to grow at a 1.4% CAGR, reaching ~20 million by 2034, driven by aging populations, obesity, sedentary lifestyles, and improved diagnostics. Endovenous laser ablation...
Read More...
Jan 16, 2026
Cancer Cachexia Drug Landscape Heats Up with Multiple Assets Advancing—7 Therapies to Watch Out
Summary Cancer cachexia is a severe, multifactorial wasting syndrome affecting most advanced cancer patients, with no approved therapies in the US or Europe and only ADLUMIZ approved in Japan, underscoring a major unmet need. Despite the historical treatment gap, the cancer cachexia pipeline is now rapidly e...
Read More...
Jan 15, 2026
Medtronic Diabetes Secures FDA Clearance for MiniMed Go™ Smart MDI Platform; Neurolief Achieves FDA PMA Approval for Novel At-Home Brain Stimulation Therapy for Depression; Haemonetics Completes Acquisition of Vivasure Medical Limited; Boston Scientific Enters Agreement to Acquire Valencia Technologies; Butterfly Medical Completes Pivotal Trial for Minimally Invasive BPH Therapy; TYBR Health Announces First U.S. Clinical Use of the B3 GEL™ System
Medtronic Diabetes Announced FDA Clearance for MiniMed Go™ Smart MDI System Featuring Instinct Sensor Made by Abbott On January 12, 2026, Medtronic, a global leader in healthcare technology, announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for its MiniMed Go™ app. The MiniM...
Read More...
Jan 14, 2026
Vital Sign Monitoring Devices: Transforming Healthcare Through Continuous Patient Surveillance
In the rapidly shifting landscape of modern healthcare, the traditional boundaries of the hospital ward are dissolving. The emergence of Vital Sign Monitors (VSM) and External Remote Patient Monitoring (RPM) devices represents one of the most significant shifts in clinical practice since the invention of the stetho...
Read More...
Jan 13, 2026
Insilico Medicine Moves Garutadustat into Phase IIa Following First Patient Dosing; Sustained Therapeutics Reports Encouraging Phase 2 Outcomes for Long-Acting Non-Opioid Chronic Pain Drug; ZYUS Life Sciences Shares Early Results from Ongoing Phase 2a UTOPIA-1 Pain Trial; Merck Advances KRAS G12C Program With Phase 3 Calderasib Combination Study in NSCLC; Sanofi’s Teizeld Gains EU Approval for Early-stage Type 1 Diabetes
Insilico Medicine Doses First Patient in Phase IIa Trial of Garutadustat for Inflammatory Bowel Disease Insilico Medicine has dosed the first patient in its Phase IIa clinical trial of Garutadustat, an AI-designed small-molecule therapy being developed for Inflammatory Bowel Disease (IBD), specifically ulcerativ...
Read More...
Jan 12, 2026
Chronic Hepatitis B: The Silent Epidemic Hiding in Plain Sight
Summary Chronic hepatitis B continues to pose a major global health challenge, affecting millions globally. ~5 million prevalent CHB cases across the 7MM in 2024. No complete cure exists yet, but advances in antivirals and novel modalities are reshaping therapeutic outcomes and hope for a functional cure. ...
Read More...
Jan 09, 2026
Vitiligo Treatment Drug Pipeline Accelerates with Late-Stage Immune-Targeting Therapies
Vitiligo represents a significant yet underrecognized health burden globally. Vitiligo, a chronic autoimmune depigmenting disorder affecting 11.7 million individuals across the leading markets in 2024, is undergoing a seismic shift in therapeutic approaches. The condition typically emerges during the second and thi...
Read More...